| pubmed-article:9871766 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9871766 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:9871766 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:9871766 | lifeskim:mentions | umls-concept:C1511695 | lld:lifeskim |
| pubmed-article:9871766 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:9871766 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:9871766 | lifeskim:mentions | umls-concept:C1513016 | lld:lifeskim |
| pubmed-article:9871766 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:9871766 | pubmed:dateCreated | 1999-3-11 | lld:pubmed |
| pubmed-article:9871766 | pubmed:abstractText | Matrix metalloproteinase inhibitors of general formula (1) were synthesised by a route involving an Ireland-Claisen rearrangement which enables systematic modification of the substituent alpha to the hydroxamic acid. An analogue (12c) possessing an alpha-cyclopentyl group is a potent broad spectrum inhibitor that displays high and sustained blood levels following oral dosing in both the rat and marmoset ex-vivo bioassays. This compound and analogues are also potent inhibitors of TNF alpha release. | lld:pubmed |
| pubmed-article:9871766 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9871766 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9871766 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9871766 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9871766 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9871766 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9871766 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9871766 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9871766 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9871766 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9871766 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:MillerKK | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:DrummondA HAH | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:WhittakerMM | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:ThomasWW | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:DaviesS JSJ | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:MartinF MFM | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:BeckettR PRP | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:LewisC NCN | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:PrattL MLM | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:ManganMM | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:CourtneyP FPF | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:DavidsonA HAH | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:ToddR SRS | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:CossinsJJ | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:RickettsM LML | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:CorkillD JDJ | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:HelfrichKK | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:BellamyC LCL | lld:pubmed |
| pubmed-article:9871766 | pubmed:author | pubmed-author:NayeePP | lld:pubmed |
| pubmed-article:9871766 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9871766 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:9871766 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:9871766 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9871766 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9871766 | pubmed:pagination | 1359-64 | lld:pubmed |
| pubmed-article:9871766 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:meshHeading | pubmed-meshheading:9871766-... | lld:pubmed |
| pubmed-article:9871766 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9871766 | pubmed:articleTitle | The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement. | lld:pubmed |
| pubmed-article:9871766 | pubmed:affiliation | British Biotech Pharmaceuticals Limited, Cowley, Oxford. | lld:pubmed |
| pubmed-article:9871766 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:9871766 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9871766 | lld:pubmed |
